Ayman Al-Hendy to Pyrimidines
This is a "connection" page, showing publications Ayman Al-Hendy has written about Pyrimidines.
Connection Strength
0.943
-
Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert Opin Drug Saf. 2022 Apr; 21(4):477-486.
Score: 0.161
-
Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model. Reprod Sci. 2022 03; 29(3):781-790.
Score: 0.160
-
Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 05; 31(5):698-705.
Score: 0.160
-
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.
Score: 0.146
-
Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020 01 23; 382(4):328-340.
Score: 0.142
-
Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 11; 132(5):1252-1264.
Score: 0.131
-
Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 2022 09 17; 400(10356):896-907.
Score: 0.043